Interestingly, luminal and HER2-positive breast cancer cell lines are particularly responsive to KDM5 catalytical inhibition or silencing [9, 11, 19–21], whereas basal lines are not [22, 23]. This evidence concerns the gene ERBB2 and breast carcinoma.